YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[short sale] abluecup As October begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 39 stocks with short interest above 20% of shares outstandi…
It has been about a month since the last earnings report for Tango Therapeutics, Inc. (TNGX). Shares have lost about 6.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earni…
[short sale] abluecup As September begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 44 stocks with short interest above 20% of shares outstan…
Revolution Medicines RVMD announced that the FDA has approved its RAS inhibitor daraxonrasib for previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The drug will be marketed under the brand name Rasonque.…
Tango Therapeutics TNGX incurred a loss of 37 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 31 cents. The company had reported a loss of 35 cents per share in the year-ago quarter. Coll…
BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Dr. B…
BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Dr. B…
The second-quarter 2026 earnings season is currently in full swing. The scorecard for the Medical sector is pretty good so far. The sector primarily comprises pharma/biotech and medical device companies. The earnings season for the pharma/…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Short interest data from late July 2026 highlights deeply divided investor sentiment across the healthcare sector. St…
Revolution Medicines RVMD announced that the FDA has accepted its regulatory filing seeking approval for its lead candidate, daraxonrasib, for previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The submiss…
Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 affordable biotech stocks to buy right now. On June 29, Canaccord Genuity increased its target price on Tango Therapeutics Inc. (NASDAQ:TNGX) from $42 to $46, resulting in more than 53…
There's no shortage of investing strategies, but growth investing remains one of the most popular approaches. Stocks that climb 50%, 100%, or more over a relatively short period rarely do so by chance. In many cases, the move is driven by…
Tango Therapeutics TNGX is becoming a clearer test of how precision oncology can shape biotech value in 2026. Its story now centers on MTAP-deleted cancers, synthetic lethality and targeted combinations. For investors, the issue is not whe…
Tango Therapeutics TNGX has become one of 2026's more dramatic biotechnology stories, with shares up 224.3% year to date and 404.1% over the past year. That rally reflects real clinical progress, but it also raises the bar. Tango remains a…
Tango Therapeutics TNGX is moving into a decisive period as vopimetostat becomes the center of the investment case. The stock story now rests on MTAP-deleted cancers, 2026 clinical updates and the risks that come with a focused clinical-st…
XBI has “moved higher a record 12 of 13 months,” Mizuho healthcare sector specialist Jared Holz wrote Friday. Continue Reading
(RTTNews) - Tango Therapeutics, Inc. (TNGX), a clinical-stage biotechnology company, announced the appointment of Robert Azelby to its Board of Directors. Azelby brings more than 30 years of experience in executive management, commercial p…
Revolution Medicines recently reported detailed Phase 3 RASolute 302 data showing once-daily oral daraxonrasib delivered unprecedented overall and progression-free survival benefits versus standard chemotherapy in previously treated metast…
Tango Therapeutics (TNGX [https://seekingalpha.com/symbol/TNGX]) announced the pricing [https://seekingalpha.com/pr/20546196-tango-therapeutics-announces-pricing-of-600-million-upsized-public-offering] of an upsized underwritten public off…
(RTTNews) - Tango Therapeutics, Inc. (TNGX), a clinical-stage precision oncology company, priced the public offering of 18.17 million shares at $30.00 per share and pre-funded warrants to purchase up to 1.833 million shares at $29.99 per p…
BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today…
Shares of Tango Therapeutics TNGX surged 53% on Monday after the company reported encouraging initial data from an ongoing phase I/II study evaluating combination treatments involving its investigational drug, vopimetostat. The study is as…
Boston-headquartered Tango Therapeutics (TNGX) stock surged on Monday, driven by encouraging results from a pancreatic cancer trial. TNGX is a clinical-stage biotech firm focused on discovering and delivering next-gen precision cancer medi…
The targeted oncology sector is shifting after GSK (GSK [https://seekingalpha.com/symbol/GSK]) decided to buy [https://seekingalpha.com/news/4601644-gsk-to-buy-nuvalent-for-106b] Nuvalent (NUVL [https://seekingalpha.com/symbol/NUVL]) for $…
(RTTNews) - Today's top gainers include Tango Therapeutics, following encouraging pancreatic cancer trial data; Aspire Biopharma, ahead of upcoming milestones; Alvotech, after FDA acceptance of its interchangeable biosimilar to Entyvio for…
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Tango Therapeutics stock skyrocketed Monday after the biotech company added to the Revolution Medicines' results in pancreatic cancer. Continue Reading
Tango Therapeutics stock soars after the biotech company announces initial data from its ongoing study on pancreatic cancer. An analyst calls the results ‘unprecedented.’ Continue Reading
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday, hinting at possible breakout opportunities. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. Price swings ahead of the…
Tango Therapeutics (TNGX) said Monday that initial results from its phase 1/2 trial of vopimetostat, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Tango Therapeutics, Inc. Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting durability of…
Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 15, the price target on Tango Therapeutics Inc. (NASDAQ:TNGX) was increased from $28 to $55 by Leerink. Follow…
Erasca Inc. (NASDAQ:ERAS) is one of the best growth stocks under $20 to buy. On May 11, Erasca reported positive progress for its precision oncology pipeline, highlighting monotherapy efficacy and a favorable safety profile for its lead ca…
Shares of Revolution Medicines RVMD were rising in pre-market today after the company reported full results from the phase III RASolute 302 study, which evaluated lead candidate daraxonrasib in previously treated patients with metastatic p…
Key Points RTW Investments added 11,809,392 shares of Tango Therapeutics last quarter; the estimated transaction value was $164.37 million based on average prices during the quarter. The quarter-end position value rose by $265.04 million,…
On May 15, 2026, RTW Investments disclosed a major buy of Tango Therapeutics(NASDAQ:TNGX), acquiring 11,809,392 shares—an estimated $164.37 million trade based on quarterly average pricing. What happened According to a Securities and Excha…